Table 1 Baseline characteristics by initial dosing strategy of thromboprophylaxis
From: Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
Total (n = 152) | Initial dosing strategy of thromboprophylaxis | p-valued | |||
|---|---|---|---|---|---|
Low dosea (n = 67) | Medium doseb (n = 48) | High dosec (n = 37) | |||
Age, years | 61 (52–69) | 63 (52–71) | 58 (51–66) | 63 (54–70) | 0.39 |
Male sex, No. (%) | 125 (82.2) | 59 (88.1) | 35 (72.9) | 31 (83.8) | 0.12 |
BMI, kg/m2 | 28.4 (25.8–32.5) | 27.7 (25.5–30.6) | 29.4 (26.5–34.3) | 28.4 (25.1–32.8) | 0.10 |
BMI ≥ 30 kg/m2, No. (%) | 58 (39.7) | 20 (31.8) | 23 (48.9) | 15 (41.7) | 0.18 |
Tobacco use | |||||
Never, No. (%) | 79 (52.0) | 32 (47.8) | 28 (58.3) | 19 (51.4) | 0.53 |
Former smoker, No. (%) | 49 (32.2) | 24 (35.8) | 12 (25.0) | 13 (35.1) | 0.40 |
Current smoker, No. (%) | 7 (4.6) | 3 (4.5) | 3 (6.3) | 1 (2.7) | 0.79 |
Comorbidities | |||||
Hypertension, No. (%) | 69 (45.4) | 32 (47.8) | 20 (41.7) | 17 (46.0) | 0.83 |
Diabetes without complications, No. (%) | 19 (12.5) | 8 (11.9) | 6 (12.5) | 5 (13.5) | 0.99 |
Diabetes with complications, No. (%) | 6 (4.0) | 4 (6.0) | 0 (0.0) | 2 (5.4) | 0.24 |
Obstructive pulmonary disease, No. (%) | 30 (19.7) | 12 (17.9) | 11 (22.9) | 7 (18.9) | 0.81 |
Ischemic heart disease, No. (%) | 12 (7.9) | 6 (9.0) | 2 (4.2) | 4 (10.8) | 0.51 |
Renal failure, No. (%) | 9 (5.9) | 6 (9.0) | 3 (6.3) | 0 (0.0) | 0.17 |
Liver disease, No. (%) | 3 (2.0) | 1 (1.5) | 1 (2.1) | 1 (2.7) | 0.99 |
Immunosuppression, No. (%) | 8 (5.3) | 5 (7.5) | 1 (2.1) | 2 (5.4) | 0.53 |
Malignancy, No. (%) | 9 (5.9) | 6 (9.0) | 1 (2.1) | 2 (5.4) | 0.34 |
Psychiatric disorder, No. (%) | 26 (17.1) | 11 (16.4) | 9 (18.8) | 6 (16.2) | 0.96 |
Chronic medication | |||||
Vitamin K antagonist, No. (%) | 1 (0.7) | 0 (0.0) | 0 (0.0) | 1 (2.7) | 0.24 |
Direct oral anticoagulation, No. (%) | 8 (5.3) | 3 (4.5) | 1 (2.1) | 4 (10.8) | 0.24 |
Antiplatelet therapy, No. (%) | 15 (9.9) | 9 (13.4) | 3 (6.3) | 3 (8.1) | 0.47 |
Duration of symptoms prior to admission | |||||
Hospital admission, days | 9 (7–12) | 9 (6–13) | 8 (6–12) | 10 (7–14) | 0.18 |
ICU admission, days | 12 (8–14) | 12 (8–14) | 10 (8–14) | 13 (10–14) | 0.13 |
SAPS III-score | 56 (50–60) | 57 (53–64) | 54 (49–59) | 55 (53–60) | 0.25 |
< 50, No. (%) | 34 (22.4) | 15 (22.4) | 13 (27.1) | 6 (16.2) | 0.53 |
50–59, No. (%) | 75 (44.7) | 31 (46.3) | 25 (52.1) | 19 (51.4) | 0.76 |
≥ 60, No. (%) | 43 (28.3) | 21 (31.3) | 10 (20.8) | 12 (32.4) | 0.41 |
Invasive Respiratory support, No. (%) | 104 (68.4) | 50 (74.6) | 34 (70.8) | 20 (54.1) | 0.09 |
Coagulation, Inflammatory and creatinine tests at baseline | |||||
Fibrin-D-dimer, mg/L FEU | 1.5 (0.90–3.9) | 1.8 (1.1–8.4) | 1.1 (0.7–2.4) | 1.3 (0.7–2.9) | 0.12 |
CRP, mg/L | 195 (134–270) | 198 (134–268) | 203 (151–255) | 183 (130–287) | 0.81 |
Hemoglobin, g/L | 129 (118–136) | 127 (118–137) | 130 (119–137) | 127 (113–135) | 0.39 |
Creatinine, µmol/L | 70 (57–88) | 74 (61–92) | 69 (48–87) | 62 (50–74) | 0.12 |
Platelet count, 109/L | 264 (195–339) | 255 (183–332) | 261 (219–318) | 302 (225–391) | 0.16 |
INR | 1.1 (1.0–1.1) | 1.1 (1.0–1.1) | 1.1 (1.0–1.1) | 1.0 (1.0–1.2] | 0.89 |
APTt, s | 26 (24–29) | 25 (24–29) | 26 (23–27) | 27 (25–30) | 0.32 |
Fibrinogen, g/L | 6.7 (5.5–8.0) | 6.7 (5.6–7.7) | 7.2 (6.4–8.3) | 6.7 (5.4–7.7) | 0.47 |